Microbot Medical Inc. announced on November 5, 2025 that its LIBERTY Endovascular Robotic System will enter a limited market release (LMR) in the United States. The LMR marks the first commercial deployment of the company’s single‑use, remotely operated platform, which received FDA 510(k) clearance in September 2025.
The LMR will focus on high‑volume regions where the company has already seen preliminary demand. Microbot has secured a third‑party logistics partner and expanded its commercial leadership team to support the rollout, with the goal of collecting real‑world data and ensuring consistent quality and performance as early adopters begin using the system.
The move signals a critical transition from a clinical‑stage to a commercial‑stage company. By generating revenue from the LMR, Microbot can validate its technology in real‑world settings and build a pipeline of data that will inform a broader market launch. The U.S. peripheral vascular procedures market, estimated at 2.5 million procedures annually, could expand to over six million with recent patent extensions, offering a sizable addressable market for LIBERTY’s single‑use, remote‑operation advantage.
CEO Harel Gadot emphasized the company’s enthusiasm for the commercialization phase, noting that LIBERTY is the world’s first single‑use robotic system and that the LMR will enable responsible support of early adopters while laying the groundwork for a full market launch at the Society of Interventional Radiology conference in April 2026. Gadot highlighted the system’s ergonomic benefits and cost‑efficiency as key differentiators against competitors such as Robocath, Rapid Medical, CMR, Corindus, Medtronic, and Stryker.
The announcement was well received by investors, with a positive market reaction. Analysts have noted the significance of the LMR as a milestone that could accelerate revenue generation and validate the company’s business model.
Microbot’s balance sheet remains strong, with no debt and a cash runway exceeding three years. While the company has historically reported losses, the LMR represents the first opportunity to generate revenue and potentially shift the company toward profitability. The planned full market release in April 2026 will broaden the product’s reach and could unlock substantial revenue streams if the early‑adopter data confirms the system’s performance and cost advantages.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.